secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sionna Therapeutics, Inc. (SION)
CIK:        0002036042
Form:       8-K
Filed at:   2026-08-10T11:15:06+00:00
Accession:  0001193125-26-341230
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sionna's SION-719 Phase 2a misses sweat chloride endpoint; program halted as add-on
--------------------------------------------------------------------------------

- SION-719 Phase 2a missed key endpoint: -1.0 mmol/L placebo-adjusted sweat chloride change (p=0.7); not advancing as add-on to SOC.
- Phase 1 of SION-451 dual combos met safety/PK goals; SION-451 + SION-2222 preferred; evaluating next steps.
- Q2 cash $268.3M; plans to preserve capital while assessing SION-451 program.
- SION-719 was well tolerated; no serious AEs; potential confounders (variability, Trikafta exposure) under review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2036042/000119312526341230/0001193125-26-341230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2036042/000119312526341230/d135438d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-341230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer